Industry

TTHX1114 has the potential to be the first pharmacologic treatment for corneal endothelial dystrophies CHICAGO–(BUSINESS WIRE)–Trefoil Therapeutics, a clinical-stage biotechnology company focused on restoring sight to people with corneal diseases, today announced positive Phase 2 results for TTHX1114 in patients with Fuchs Endothelial Corneal Dystrophy (FECD). TTHX1114, a proprietary engineered fibroblast growth factor-1 (FGF1) variant, … [Read more…]

ALAMEDA, Calif.–(BUSINESS WIRE)–#CRISPR–Scribe Therapeutics Inc., a molecular engineering company pioneering a CRISPR by Design™ platform for genetic medicine, today announced it will participate in two upcoming investor conferences: Scribe co-founder and CEO Benjamin Oakes will participate in a panel titled “Gene Editing: Next-Generation Technologies Worth Watching,” at 9:30 a.m. ET on Oct. 3, 2022, at … [Read more…]

Sitagliptin is an active ingredient in JANUVIA®, JANUMET® and JANUMET® XR RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Court of Appeals for the Federal Circuit ruled in favor of the company in a patent challenge brought by Mylan Pharmaceuticals, Inc. (now … [Read more…]

Latest ‘Back on the Books’ survey suggests lack of knowledge may keep women from receiving lifesaving health care ALEXANDRIA, Va.–(BUSINESS WIRE)–A new survey by the Prevent Cancer Foundation® reveals an alarming statistic: almost half (49%) of American women 40 and older report they have not had a breast cancer screening in more than two years. … [Read more…]

VieCure Inc., a cancer care company with a market-leading artificial intelligence, informatics, and clinical decision support platform, announces further facility investments and employee expansion in the Denver Tech Center DENVER–(BUSINESS WIRE)–VieCure, a cancer care company with a market-leading artificial intelligence, informatics, and clinical decision support platform, announced today the opening of the Dr. Don Iverson … [Read more…]

Largest study to-date of corneal cross-linking to treat keratoconus Company aims to develop leading standard of care for keratoconus and corneal ectasia SHERBORN, Mass.–(BUSINESS WIRE)–CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today published results of the EpiSmart cross-linking Phase 2 study for keratoconus in Cornea: The Journal of Cornea and … [Read more…]

Agilent will fund STEM students from underrepresented groups, and provide lab instrumentation and mentorship to support postgraduate research in the life sciences SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) is launching a partnership with Delaware State University (DSU), a leading historically Black university, to increase the share of underrepresented students entering STEM fields, a … [Read more…]

First-of-its-kind system enables a new class of solid-state thermal management systems that is currently only possible with bulkier, mechanical alternatives PASADENA, Calif.–(BUSINESS WIRE)–DTP Thermoelectrics has been awarded a patent that opens the door for solid-state deep cooling thermal management. The patent is based on theoretical and analytical models that have been validated through the fabrication … [Read more…]

Thursday, October 13, 2022, 6:00 -7:00 PM EDT; Cambridge, MA, USA A look at the benefits and challenges of decentralized clinical trials and the implications for their long-term adoption CAMBRIDGE, Mass.–(BUSINESS WIRE)–Join PROMETRIKA and guest Ken Getz, MBA, Executive Director of the Tufts Center for the Study of Drug Development, to explore the ongoing experience … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Asia Pacific Air Treatment Market Forecast to 2028 – COVID-19 Impact and Regional Analysis By Type and Application” report has been added to ResearchAndMarkets.com’s offering. The air treatment market in Asia Pacific is expected to grow from US$1,964.85 million in 2021 to US$2,822.13 million by 2028; it is estimated to register a CAGR … [Read more…]